SIGN IN
Process Development Senior Associate - Drug Substance Technologies - Synthetics (DSTS) jobs in United States
cer-icon
Apply on Employer Site
company-logo

Amgen · 4 hours ago

Process Development Senior Associate - Drug Substance Technologies - Synthetics (DSTS)

Amgen is a leading biotechnology company dedicated to serving patients living with serious illnesses. They are seeking a Process Development Senior Associate to join their Drug Substance Technologies group, where the role involves collaborating with chemists and engineers to develop and implement drug manufacturing processes.
BiotechnologyHealth CareManufacturingPharmaceutical
check
Comp. & Benefits
check
H1B Sponsor Likelynote

Responsibilities

Work within a drug substance team comprised of chemists, engineers, and attribute scientists to solve technical problems
Contribute to the invention of synthetic routes and development of safe, robust, and cost-effective processes to manufacture synthetic and hybrid drug substances
Support cGMP manufacturing and technology transfer to our internal manufacturing facilities and external contract manufacturers
Support process characterization activities, including process understanding and modeling
Contribute to drug substance development teams by providing experimental results, technical updates, documentation, data interpretation, recommendations, etc
Works regularly with a supervisor to advance projects within required deadlines
Work cross-functionally to deliver regulatory documents and support regulatory filings
Follows good laboratory documentation practices and standard operating procedures

Qualification

Organic chemistryBiochemistryAnalytical characterization techniquesSynthetic methodologyProcess developmentProject planningCommunication skillsTeam collaboration

Required

High school diploma / GED and 6 years of Scientific experience OR
Associate's degree and 4 years of Scientific experience OR
Bachelor's degree and 2 years of Scientific experience OR
Master's degree

Preferred

M.S. in organic chemistry or biochemistry/chemical biology with a specialization in synthetic/conjugation chemistry, synthetic methodology, total synthesis, peptide/protein chemistry, or oligonucleotide chemistry
Prior experience with ADC development, bioconjugation, or related modalities
Proficiency in analytical characterization techniques such as Hydrophobic Interaction Chromatography (HIC)-HPLC, Size Exclusion Chromatography (SEC), Liquid Chromatography–Mass Spectrometry (LC-MS), Ion-Exchange (IEX), and Reversed Phase (RP)-HPLC
Experience working in pharmaceutical industry with expertise in synthetic peptide, oligonucleotide, and/or antibody drug conjugate process development
Demonstrated ability to work in a chemistry laboratory with minimal supervision
Ability to independently collect and interpret analytical results (NMR, HPLC, MS, IR, Raman, etc)
Excellent written and verbal communication skills, ability to multitask, effectively plan and follow through on projects
Experience working in cross-functional or matrixed teams
A research summary included with CV is strongly encouraged

Benefits

A comprehensive employee benefits package, including a Retirement and Savings Plan with generous company contributions, group medical, dental and vision coverage, life and disability insurance, and flexible spending accounts
A discretionary annual bonus program, or for field sales representatives, a sales-based incentive plan
Stock-based long-term incentives
Award-winning time-off plans
Flexible work models where possible.

Company

Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.

H1B Sponsorship

Amgen has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (429)
2024 (485)
2023 (485)
2022 (540)
2021 (460)
2020 (444)

Funding

Current Stage
Public Company
Total Funding
$28.5B
2022-12-12Post Ipo Debt· $28.5B
1983-06-17IPO

Leadership Team

leader-logo
Robert Bradway
Chairman and Chief Executive Officer
linkedin
leader-logo
Jay Bradner
Executive Vice President of R&D, and Chief Scientific Officer
linkedin
Company data provided by crunchbase